Aetna Capsule Endoscopy Coverage Update

Covered Indications (Medical Necessity)

Aetna considers capsule endoscopy medically necessary for any of the following indications:

Medical necessity indications list: 1. Evaluation of locoregional carcinoid tumors of the small bowel in persons with carcinoid syndrome; OR 2. Evaluation of persons with celiac disease with positive serology who are unable to undergo esophagogastroduodenoscopy (EGD) with biopsy; OR 3. Re-evaluation of persons with celiac disease who remain symptomatic despite treatment and there is no suspected or confirmed GI obstruction, stricture, or fistulae; OR 4. Initial diagnosis in persons with suspected Crohn's disease (abdominal pain or diarrhea plus ≥1 sign of inflammation or bleeding) when conventional diagnostic tests (small-bowel follow-through or abdominal CT/CT enterography and EGD and colonoscopy) have not demonstrated disease; OR 5. Re-evaluation of persons with Crohn's disease who remain symptomatic despite treatment and there is no suspected or confirmed GI obstruction, stricture, or fistulae; OR 6. Investigating suspected small intestinal bleeding in persons with objective evidence of recurrent, obscure GI bleeding (eg, persistent/recurrent iron-deficiency anemia, persistent/recurrent positive fecal occult blood test, or visible bleeding) who have had upper and lower endoscopies within the past 12 months that failed to identify a bleeding source; OR 7. Surveillance of small intestinal tumors in persons with Lynch syndrome, Peutz-Jeghers syndrome or other polyposis syndromes affecting the small bowel; OR 8. Screening or surveillance of esophageal varices in cirrhotic persons with significantly compromised liver function (Child-Pugh Class B or greater) or when standard upper endoscopy with sedation/anesthesia is contraindicated.

Exact wording preserved from policy.

Clinical indications and limitations

Clinical indications and condition‑specific limitations and operational considerations:

Obscure GI bleeding: Primary indication: evaluate obscure gastrointestinal bleeding after negative prior ileocolonoscopy and EGD; not useful as an acute localization tool because CE requires hours to complete and results are generally not immediately available.

Guideline and background context supports OGIB as main CE indication; cite AGA and technology assessments.

Suspected small-bowel Crohn's disease: Use CE for suspected Crohn's disease only after conventional diagnostic tests are negative; preingestion radiologic screening (eg, CT or small-bowel follow-through) is recommended to exclude asymptomatic strictures because retention risk (~5%) is significant.

Lack of biopsy capability and retention risk highlighted; imaging to exclude strictures recommended.

Esophageal indications: Esophageal capsule has been evaluated for GERD, Barrett's esophagus, and varices but has variable sensitivity and cannot obtain biopsies; it may be considered when EGD is contraindicated or refused but is not equivalent to EGD for variceal detection.

Sensitivity/specificity variable; cannot replace EGD.

Celiac disease:

Evidence summaries / considerations

Key evidence summaries and clinical considerations relevant to coverage decisions:

PCC2 / CCE-2 performance: Second-generation colon capsule (PCC2/CCE-2) pooled sensitivity for polyps ≥6 mm ~87% and for ≥10 mm ~89% in meta-analyses; capsule retention in these studies ~0.8% and adequacy of bowel prep varied widely.

Health Quality Ontario and Eliakim et al. findings summarized.

Esophageal varices evidence: Pooled sensitivity of CE for any-size esophageal varices ≈84.8% with specificity ≈84.3%; sensitivity for large varices lower (~73.7%); therefore CE cannot replace EGD for initial diagnosis but may be considered when EGD is contraindicated.

Cochrane/systematic review pooled estimates.

Patency capsule and retention: Passage of an intact patency capsule within 72 hours has been used to demonstrate intestinal patency prior to CE, but evidence is limited and adverse events (including obstruction) have been reported; clinical judgment and pre-procedure imaging remain important.72 hours

Appropriate Use: Post-Incomplete Colonoscopy or When Colonoscopy Not Feasible

Consider colon capsule endoscopy (CCE) when ALL of the following apply (contexts in which studies demonstrated utility):

Context requirements: Patient has incomplete colonoscopy (IC) or is unable/unwilling to undergo conventional colonoscopy AND prior colonoscopy details (segment reached, reason for incompleteness) are documented.

Studies of CCE after incomplete OC enrolled such patients and documented prior OC reach/prep.

Adequate bowel preparation and completion expected: Protocolized and adequate bowel cleansing and booster regimens are used and documentation supports anticipated completion/excretion; inadequate cleansing or incomplete transit substantially reduces diagnostic reliability.

Studies report variable cleansing adequacy and completion rates; inadequate prep may render study non-diagnostic.

Device generation: Prefer use of 2nd-generation CCE (PillCam Colon 2 / CCE-2) given higher sensitivity reported in feasibility and multi-center studies.

Multiple trials used CCE-2 and reported superior sensitivity compared with 1st-generation devices.

Evidence summaries / coverage-relevant findings

Study-based coverage-relevant findings and operational points:

Visualization after incomplete colonoscopy: Baltes et al. (PillCamColon2) visualized colonic segments missed by incomplete colonoscopy in 90% (protocol A) to 97% (protocol B) of patients; significant polyps detected in 24% of cases; patients with stenosis were excluded in that trial.

One retention reported (1.4%) in ileum; bowel cleansing adequate in 67%.

Complete exams improve sensitivity: In screening/fecal immunochemical test–positive cohorts, CCE per-patient sensitivity for >9 mm polyps was superior to colonoscopy only in complete CCE examinations; incomplete CCE exams reduce reliability.>9 mm

Kobaek-Larsen and others noted superior sensitivity only for complete exams.

CCE in first-degree relatives of CRC patients: In FDR screening cohorts, CCE sensitivities for ≥6 mm lesions were ~91% and for ≥10 mm ~89%, with post-CCE referral rates to colonoscopy reported (eg, 37% and 18%).

Coverage and conditional use

Coverage considerations and conditional use derived from the evidence:

Esophageal varices coverage stance: CE for esophageal varices may be acceptable when EGD is refused or contraindicated, but CE sensitivity is insufficient to replace EGD for initial diagnosis; documentation of refusal/contraindication should be provided.sensitivity variable (~73.7%–84.8%)

High specificity suggests a role to confirm suspected varices when EGD not possible.

CCE-2 conditional use: CCE-2 demonstrates high per-patient sensitivity and specificity for polyps, but incomplete transit and variable bowel prep limit screening utility; consider CCE as a triage/filter test between FIT and colonoscopy or when colonoscopy is not feasible, with documentation of adequate prep and complete transit.sensitivity ~0.85-0.87; specificity up to 0.95 for larger polyps

Systematic reviews report high accuracy but emphasize completion rates and prep quality.

Pan-enteric CE in Crohn disease:

Evidence summaries and applicability

Applicability notes and limitations for different capsule endoscopy variants:

CCE diagnostic accuracy and limits: Meta-analyses of CCE-2 report high per-patient sensitivity/specificity for polyps (any size, ≥6 mm, ≥10 mm) but bowel preparation adequacy (40%–100%) and complete transit rates (57%–100%) vary substantially, limiting population screening applicability.

Patient perspective and prep adherence also limit implementation.

Magnetic-assisted CE and gastric lesions: Magnetically controlled CE shows pooled sensitivity (~87%) for gastric lesions in pooled analyses but requires further comparative studies before it can substitute conventional gastroscopy.

Promising but not yet routine practice.

Pan-enteric CE applicability: PCE may offer comprehensive evaluation in Crohn's disease with high sensitivity for active inflammation, but lack of transmural assessment and standardized scoring systems limit its replacement of cross-sectional imaging or ileo-colonoscopy in many settings; proven small-bowel patency was required in trials.

Best applied to non-stricturing disease and with documented patency.

Aetna considers capsule endoscopy experimental and investigational for numerous indications where effectiveness has not been established. Examples include: screening (other than esophageal varices); initial test in diagnosing GI bleeding; evaluation of abdominal pain unless specific medical-necessity criteria are met; use in persons with known or suspected GI obstruction, strictures, or fistulas; use in persons with cardiac pacemakers or other implanted electro-medical devices; use in persons with dysphagia or other swallowing disorders; use for colorectal cancer screening or routine detection of colorectal polyps; confirming pathology identified by other diagnostic means; detection of gastric varices or hookworms; diagnosing mucosal inflammation in ulcerative colitis or intestinal graft-versus-host disease; repeat use to verify surgical effectiveness; use of the Agile patency capsule for patency testing; use of the Cytosponge or Esophageal String Test for routine diagnostic screening; magnetic-assisted capsule endoscopy for upper-GI screening; use of artificial intelligence for colon CE image review; and video CE for graft-versus-host disease, among other listings in the policy.

Capsule endoscopy should not be performed in patients with obstructive symptoms or with endoscopic or radiographic evidence of small-bowel narrowing in the setting of Crohn’s disease due to the risk of capsule retention (estimated at approximately 5% in this population). Preingestion imaging such as small-bowel follow-through or CT enterography is recommended to exclude asymptomatic strictures before CE in these patients.

Known or suspected gastrointestinal obstruction, strictures, or fistulae are contraindications to capsule endoscopy unless intestinal patency has been demonstrated. The Agile Patency System has been used to assess patency (passage of an intact patency capsule within 72 hours has been reported), but evidence for routine use of patency capsules is limited and adverse events have been reported; clinicians should document evaluation for obstruction prior to CE.

Capsule endoscopy is a diagnostic-only modality and is not an appropriate substitute for colonoscopy when histologic sampling or immediate polypectomy is required. Studies that do not include contemporaneous colonoscopy cannot establish sensitivity or specificity for lesion detection; when tissue diagnosis or therapeutic intervention is indicated, optical colonoscopy remains the standard.

Some clinical trials excluded patients with known intestinal stenosis. For example, the Baltes (PillCamColon2) trial specifically excluded patients with stenosis when evaluating CCE after incomplete colonoscopy, and therefore the trial results do not apply to patients with known stricturing disease.

Patients with intestinal stenosis were excluded from the Baltes PillCamColon2 study; additionally, pan-enteric/pan-intestinal capsules and PillCam Crohn’s examinations often require vigorous colonic preparation, which may limit feasibility in some patients and preclude their participation or repeat testing.

Current evidence does not support replacing EGD with capsule endoscopy for detection of esophageal varices. Meta-analytic data demonstrate variable sensitivity, and guideline reviews conclude that EGD cannot be replaced by CE for variceal detection; CE may be considered only when EGD is refused or contraindicated.

Wireless capsule endoscopy is not indicated as a routine second-line investigation for localization of primary gastro-entero-pancreatic neuroendocrine tumors (NETs) when first-line imaging has been performed; WCE may provide additional information in selected referral-center cases but is not routinely indicated.

No additional explicit exclusions were present in the extracted portion of the policy beyond those already listed; refer to the full policy for the complete exclusion list and updates.

Use of capsule endoscopy for the indications listed as experimental and investigational in this policy is considered not medically necessary because the effectiveness for those uses has not been established. Examples include screening (other than for select esophageal varices), many esophageal and gastric disease evaluations, routine colorectal cancer screening, and several investigational device- or technique-based uses named in the policy.

Evidence does not support routine use of capsule endoscopy for population-wide detection of colorectal polyps or cancers. Studies show that colon capsule performance is highly dependent on adequate bowel preparation and complete transit; current data do not establish CE as a replacement for optical colonoscopy for CRC screening.

Capsule endoscopy should not replace EGD for detection of esophageal varices in adults with cirrhosis. Systematic reviews report pooled sensitivity and specificity that are insufficient to support CE as a triage or replacement test; CE may be considered only when EGD is contraindicated or refused, with documentation of the reason.

Colon capsule endoscopy (CCE) has not been established for routine population-wide primary screening: comparative data, logistical issues (need for rigorous bowel preparation and booster timing), and variable rates of incomplete examinations limit its current use as a population screening tool.

Evidence does not establish capsule endoscopy as a routine management tool for ulcerative colitis. Although some studies suggest comparable assessment of mucosal inflammation, available guidelines and UpToDate reviews do not currently recommend CE for routine UC management, and PCE does not replace fecal calprotectin or colonoscopy because CE cannot provide histologic assessment.

Routine use of capsule endoscopy as a triage test before EGD for screening or surveillance of esophageal varices is not medically necessary due to insufficient sensitivity; CE may only be used when EGD is contraindicated or refused, and the clinical rationale should be documented.

For ulcerative colitis and inflammatory bowel disease contexts, pan-enteric capsule endoscopy (PCE) is not a replacement for fecal calprotectin testing or colonoscopy because CE lacks histologic sampling and may have limited specificity; PCE remains investigational for routine substitution of standard tests.

Within the extracted policy portion there were no additional explicit 'not medically necessary' declarations beyond those summarized above; consult the full policy text for any further statements.

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization — not specified

Prior authorization: Not specified in the provided text. The source excerpts do not list an explicit prior authorization requirement or specific PA codes for capsule endoscopy procedures. Verify payer-specific prior authorization procedures separately before scheduling.

No explicit authorization or billing requirements specified in the extracted policy text.
No explicit authorization/denial trigger present in the provided chunks.

Prior Authorization

Authorization context: after incomplete colonoscopy or when colonoscopy not feasible

Authorization context: Capsule endoscopy (including colon capsule endoscopy) is most often authorized or considered when colonoscopy is incomplete or not feasible, or when conventional investigations (EGD, colonoscopy, small-bowel follow-through, CT/CT enterography) have been performed and are non-diagnostic per the medical necessity criteria.

Use principally after incomplete colonoscopy (IC) or when colonoscopy is refused or contraindicated.
Consider CCE as an alternative filter-test between FIT and colonoscopy in some CRC screening contexts, or when colonoscopy is incomplete or not possible.

Documentation Required

Small-bowel patency required / Patency proof for PCE

Document proven small-bowel patency prior to pan-enteric or small-bowel capsule endoscopy in patients at risk for strictures. Studies of pan-enteric CE enrolled only subjects with demonstrated small-bowel patency.

Proven small-bowel patency required for PCE and other CE when small-bowel strictures are a concern.
Patency capsule documentation (e.g., intact excretion within 72 hours) has been used to demonstrate patency prior to VCE.
Imaging (CT, MRE, or small-bowel follow-through) may be required to exclude asymptomatic strictures in Crohn’s disease patients.

Documentation Required

Patency capsule documentation

Patency capsule testing: passage of an intact patency capsule (or documented intact excretion within 72 hours) provides evidence of functional luminal patency and has been used to allow safe video capsule endoscopy in patients with suspected strictures. However, evidence on patency systems is limited and adverse events have been reported.

Agile Patency System and other dissolvable patency capsules have been used to identify patients who may safely undergo CE.
Document retrieval of an intact patency capsule or other proof of patency prior to proceeding with CE in high-risk patients.

Denial Risk

Inadequate preparation / technical failure; Contraindications

Contraindications and technical failure: Do not perform capsule endoscopy in patients with known or suspected GI obstruction, strictures, or fistulae unless patency has been documented. Inadequate bowel preparation or incomplete transit leading to insufficient visualization were common exclusion triggers in trials and may result in non-diagnostic studies.

Contraindicated with obstructive symptoms or radiographic/endoscopic evidence of narrowing unless patency proven.
Inadequate preparation, poor colon cleanliness, or insufficient transit time can cause incomplete or technically inadequate CE examinations (noted as common reasons for exclusion in studies).
Retention risk exists; retained capsules may require endoscopic or surgical retrieval.

Documentation Required

Supportive documentation for medical necessity / Document prior colonoscopy reach and prep

Documentation of prior investigations and procedure details: The policy and evidence emphasize documenting prior conventional investigations and prior colonoscopy details when relevant.

Document prior conventional investigations (EGD, colonoscopy, small-bowel follow-through, CT/CT enterography) — CE is generally considered when these are negative or non-diagnostic.
Document prior colonoscopy reach and bowel prep protocol (e.g., which colonic segment was reached and which split/prep protocol was used) when CCE is performed after incomplete colonoscopy.
Document reasons when CE is used instead of EGD (e.g., patient refusal, contraindication) and that counseling occurred about comparative sensitivity and limits of CE vs EGD.

Step Therapy

Prior conventional investigations, alternatives, and step-therapy context

Alternatives and step approach: The literature and guidance note alternative diagnostic options and that no step-therapy algorithm or formal PA step requirements are specified in the extracted text.

Prior alternatives to consider after incomplete colonoscopy: CT colonography (CTC), repeat colonoscopy by expert endoscopist or with alternative scopes (pediatric, variable-stiffness, balloon-assisted), or referral to tertiary center.
Prior conventional investigations to consider before small-bowel CE: ileocolonoscopy, EGD, small-bowel follow-through, CT/CT enterography.
Step approach for CRC screening alternatives: CCE may be considered as a filter or alternative for CRC screening in some contexts (e.g., between FIT and colonoscopy), but incomplete exams limit screening utility.
No step therapy requirements described in the provided excerpts; no step-therapy algorithms or PA step requirements are specified.

Billing Rule

No explicit authorization, billing, or documentation procedures specified in this excerpt

No explicit documentation or billing rules specified in the provided text: The extracted policy chunks do not provide payer-specific documentation forms, explicit billing/coding authorization steps beyond CPT/ICD listings, or explicit denial triggers tied to administrative requirements.

No explicit authorization or billing requirements specified in the provided chunks.
No documentation requirements are present in the extracted text beyond clinical documentation items noted above.
Denial risk exists for experimental/investigational indications listed in the policy (these uses may be denied).

Documentation Required

Capsule endoscopy replacement for EGD — documentation required if used instead of EGD

Capsule endoscopy versus EGD: Capsule endoscopy sensitivity is generally insufficient to replace EGD for initial diagnosis of esophageal varices or other conditions where EGD allows tissue acquisition or therapy. If CE is used because EGD is refused or contraindicated, document the reason and counseling.

When replacing EGD (e.g., due to refusal or contraindication), document the refusal/contraindication and that counseling about limitations of CE vs EGD occurred.
CE may be considered when EGD is contraindicated or refused, but CE lacks therapeutic intervention and has lower sensitivity for some esophageal conditions.

Note

Not applicable / No additional provider-action statements present

Not applicable/placeholder items from extracted text: Several chunks contained no additional explicit provider-action, authorization, or denial-rule statements; these are noted as not described in the provided excerpts.

Not applicable in this excerpt — no explicit prior authorization statements in multiple chunks.
Not described in the provided chunks: specific PA codes, explicit denial triggers for administrative reasons, and payer-specific intake forms.

Definitions and Device Terms

Capsule endoscopy (CE) — definition

DefinitionWireless/video capsule endoscopy (CE): ingestion of a small camera-containing capsule that transmits images wirelessly to an external recorder for physician review; typically excreted within 8–72 hours.

PurposeNoninvasive diagnostic visualization of the esophagus, stomach, small bowel, or colon; diagnostic only — cannot biopsy or perform therapy.

Examples of FDA-cleared devicesIncludes PillCam variants (PillCam COLON 2, PillCam ESO, PillCam SB 2/3), Olympus small intestine capsule, and PillCam patency system as accessories.

Push enteroscopy — definition and capabilities

DefinitionPush enteroscopy: insertion of a long endoscope (approximately 4 feet) through the esophagus and stomach into the proximal small intestine to visualize mucosa and perform biopsies and therapeutic interventions.

Role vs CEHistorically the standard for diagnosing small intestinal bleeding before CE; allows tissue acquisition and intervention that CE cannot provide.

LimitationsCannot reach the entire small bowel; definitive diagnosis can be limited when lesions are distal to reach of the scope.

Obscure gastrointestinal bleeding (OGIB) — definition

DefinitionObscure gastrointestinal bleeding (OGIB): bleeding of unknown origin that persists or recurs after negative initial endoscopic evaluation (EGD and colonoscopy).

Clinical contextOGIB is the principal indication for small-bowel CE when prior ileocolonoscopy and EGD are negative; CE is not suitable for acute emergent localization.

Recommended prior testingPrior upper and lower endoscopy/ileocolonoscopy are recommended before CE for OGIB evaluation.

Capsule retention — definition and implications

DefinitionCapsule retention: failure of an ingested capsule to pass because of strictures or obstruction, which may require endoscopic or surgical retrieval.

ImplicationsRetention risk is a major concern in Crohn's disease (~5% reported proximal to unsuspected strictures) and may necessitate preingestion imaging to exclude strictures.

Contraindication noteKnown or suspected GI obstruction, strictures, or fistulae are contraindications to CE unless patency is demonstrated.

Patency capsule (Agile) — definition and safety note

DefinitionPatency capsule (Agile Patency System): a dissolvable capsule used to assess small-bowel patency prior to video capsule endoscopy ingestion.

Intended useUsed to help identify patients with strictures who may safely undergo CE by demonstrating passage/excretion of the patency capsule.

Safety noteEvidence is limited; adverse events including obstruction requiring intervention have been reported and routine use is not fully validated.

CCE-2 / PillCam Colon 2 — device definition

DefinitionCCE-2 / PillCam Colon 2: second-generation colon capsule endoscopy system with dual cameras designed to increase sensitivity for colorectal polyp detection compared with first-generation devices.

Intended roleNoninvasive visualization of the colon as an alternative or adjunct when colonoscopy is incomplete or not feasible; requires excellent bowel prep and complete transit for diagnostic accuracy.

PerformanceClinical studies report improved sensitivity for polyps >=6 mm and >=10 mm compared with earlier systems, with variable bowel cleanliness and transit completeness affecting results.

Incomplete colonoscopy (IC) — definition

DefinitionIncomplete colonoscopy (IC): a colonoscopy that fails to visualize the entire colon (e.g., due to looping, stenosis, or technical factors).

Relevance to CCECCE (particularly CCE-2) is frequently evaluated as a follow-up modality to visualize colonic segments missed by IC and has demonstrated high visualization rates in studies.

Alternative optionsOther alternatives after IC include CT colonography or repeat colonoscopy by experienced endoscopists or alternative scopes.

PillCam Crohn's score — definition

DefinitionPillCam Crohn's score: a capsule endoscopy scoring system that sums scores for the most common and most severe lesions multiplied by percentage of segmental involvement plus a stricture score to quantify panenteric inflammatory burden.

PurposeDesigned to assess and quantify inflammatory activity across the small bowel and colon in Crohn's disease using pan-enteric capsule data.

Performance noteSub-studies report good correlation and high inter-rater reliability compared with Lewis inflammatory score, but further validation is needed for responsiveness and clinical impact.

Capsule colonoscopy (CCE) — definition and use

DefinitionCapsule colonoscopy (CCE): use of wireless capsule endoscopy specifically adapted for colon imaging (e.g., PillCam Colon systems) to visualize the colon as a noninvasive alternative to optical colonoscopy.

Use casesEvaluated for colorectal cancer screening as a filter-test, for patients with incomplete colonoscopy, and for those unfit or unwilling to undergo colonoscopy.

LimitationsCCE diagnostic accuracy depends on adequate bowel preparation and complete transit; high rates of incomplete studies limit routine population screening.

Cytosponge — definition and use

DefinitionCytosponge: an ingestible gelatin-encapsulated compressed mesh sponge attached to a string that expands in the stomach and, when withdrawn, collects esophageal cells for cytology, immunohistochemistry, and molecular testing.

Intended useDeveloped for screening and surveillance of Barrett's esophagus and other esophageal pathology as a less invasive sampling alternative to endoscopic biopsy.

Evidence noteEarly studies report promising diagnostic accuracy and high patient acceptability, but most data originate from a single investigative group and require external validation.

String capsule endoscopy (SCE) — definition

DefinitionString capsule endoscopy (SCE): a wireless capsule endoscope tethered by a string to allow controlled movement and imaging of the esophagus.

Intended applicationEvaluated for esophageal variceal detection and other esophageal pathologies where controlled capsule movement improves visualization.

Safety and acceptabilitySmall studies report feasibility, safety (no device losses or string disruptions), high accuracy, and patient preference over conventional EGD in selected cirrhotic patients.

Tethered capsule endomicroscopy (TCE) — definition

DefinitionTethered capsule endomicroscopy (TCE): a tethered device that acquires microscopic images of the entire esophagus in unsedated subjects for potential screening.

Use caseDesigned for rapid, unsedated esophageal imaging in primary care/population settings as a potential screening tool for Barrett's esophagus and other pathologies.

Evidence noteFeasibility and acceptability have been reported, but diagnostic accuracy vs endoscopic biopsy requires further evaluation.

Colon capsule endoscopy (CCE-2) — second-generation definition

Definition (second-generation)Colon capsule endoscopy (CCE-2): second-generation wireless colon capsule (eg, PillCam Colon 2) with dual cameras and enhanced imaging designed for improved polyp detection compared with first-generation devices.

Clinical evaluationCCE-2 has been evaluated in multiple diagnostic accuracy studies and meta-analyses showing high per-patient sensitivity and specificity for polyps >=6 mm and >=10 mm, though completeness and bowel prep vary.

Operational noteCCE-2 requires validated bowel prep regimens and strategies (boosts/rescue agents) to maximize excretion and cleanliness for diagnostic reliability.

CCE-2 (device repeat) — device name and study link

Device naming and study linkageCCE-2 (PillCam Colon 2) is the device evaluated in multiple feasibility and comparative studies (eg, Spada 2011, Baltes 2018, Kobaek-Larsen 2018) reporting improved sensitivity for clinically relevant polyps.

Performance summaryStudies report per-patient sensitivity for >=6 mm and >=10 mm polyps typically in the 84%–89% (>=6 mm) and 88%–95% (>=10 mm) ranges in CCE-2 cohorts, with capsule excretion and adequate bowel cleanliness rates varying by protocol.

Clinical implicationCCE-2 is preferred over 1st-generation devices when considering capsule evaluation of the colon due to improved diagnostic performance.

PCE — pan-enteric capsule endoscopy definition

DefinitionPan-enteric capsule endoscopy (PCE): a pan-intestinal capsule system (eg, PillCam Crohn’s / PCC) designed to evaluate the entire GI tract including small bowel and colon in a single study.

Clinical roleUsed primarily in Crohn's disease assessment to detect active enteric inflammation across segments; may require demonstration of small-bowel patency prior to use.

LimitationsPCE provides mucosal assessment but lacks transmural evaluation; studies often excluded patients with strictures and required proven patency before ingestion.

Magnetically controlled CE — definition and intended use

DefinitionMagnetically controlled capsule endoscopy: capsule endoscopy whose movement is influenced or guided by external magnetic fields to improve visualization, particularly of the stomach/upper GI tract.

Intended useDesigned to overcome passive transit limitations of standard CE and enhance gastric/upper-GI visualization without sedation in some settings.

Evidence summaryMeta-analyses and prospective studies report pooled sensitivity around 87% for gastric lesion detection with minimal adverse events, but larger comparative trials are needed before replacing conventional gastroscopy.

Background, Evidence, and Outcomes

Capsule endoscopy is a noninvasive diagnostic procedure in which a patient swallows a camera-containing capsule that transmits images to an external recorder for physician review. CE provides endoluminal visualization of the esophagus, stomach, small bowel, and — with specialized colon capsules — the colon, but it is strictly diagnostic and cannot obtain biopsies or perform therapeutic interventions. FDA-cleared CE systems include PillCam variants and other small-intestine capsules; patency capsules exist to evaluate strictures but have limited evidence and reported adverse events. CE's clinical role includes evaluation of obscure gastrointestinal bleeding, investigation of suspected small-bowel Crohn's disease when conventional testing is negative, surveillance in select polyposis syndromes, and evaluation after incomplete colonoscopy when colonoscopy is not feasible; its limitations include inability to biopsy, dependency on bowel preparation (for colon applications), potential capsule retention in stricturing disease, and variable diagnostic accuracy across indications.

Appropriate Use and study contexts

Appropriate use contexts and study settings where CCE demonstrated utility (repeated evidence context):

Post-incomplete colonoscopy utility: Multiple prospective studies (Pioche, Spada, Nogales, Baltes) evaluated CCE in patients with incomplete colonoscopy and reported high diagnostic yield and visualization of previously missed segments (visualization rates up to 97% in protocolized regimens), with bowel cleansing adequacy and completion rates affecting diagnostic performance.

Studies excluded patients with known stenosis in some trials; one retention reported in Baltes study.

CRT/Screening contexts: In screening or FIT-positive cohorts, CCE demonstrated comparable or high per-patient sensitivity for larger polyps when complete exams are achieved (eg, per-patient sensitivity for >9 mm lesions up to 97% in complete exams), but incomplete exams impair reliability.>9 mm

Complete exam rates are critical for screening applicability.

Operational considerations: Trials used specific bowel prep and booster regimens (eg, Moviprep protocols A/B, rescue phospho-soda) and documented prior OC reach; documentation of prior colonoscopy reach and prep improves interpretation and selection for CCE.

Protocolized prep improved visualization in studies.

Key evidence summaries relevant to coverage: second-generation colon capsule systems (PCC2/CCE-2) have pooled per-patient sensitivity around ~87% for polyps ≥6 mm and higher sensitivity for larger polyps in some studies, with capsule retention rates reported around 0.8%. Comparative and feasibility studies report variable adequacy of bowel cleanliness (commonly 60–80%) and incomplete transit/excretion rates that affect diagnostic yield. In incomplete colonoscopy settings, CCE visualized missed segments in 90–97% of patients in the Baltes trial, detecting significant polyps in roughly 24% of cases; however, patients with stenosis were excluded from that study. For esophageal varices, pooled sensitivity estimates range approximately from 73.7% (large varices) up to 84.8% (any-size varices), but CE lacks sufficient sensitivity to replace EGD for routine variceal screening.

Additional evidence considerations: CE is most useful in well-defined contexts such as obscure GI bleeding after negative upper and lower endoscopy, post-incomplete colonoscopy evaluation, surveillance for selected small-bowel polyposis syndromes, and selected Crohn’s disease assessments when strictures have been excluded. Study limitations across the literature include heterogeneity in bowel preparation regimens, variable rates of complete examinations, exclusion of patients with stenosis from many trials, and limited data demonstrating that CE-based changes in management improve clinical outcomes. Emerging modalities (magnetically controlled CE, pan-enteric capsules, Cytosponge, AI-assisted image review) show promise but require further validation before routine clinical adoption.

91110	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus through ileum, with physician interpretation and report.
91111	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with physician interpretation and report.
91113	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report.

C7A.010 - C7A.019	Malignant carcinoid tumors of the small intestine.
D50.0	Iron deficiency anemia secondary to blood loss (chronic).
K90.0	Celiac disease.
K50.00 - K50.919	Crohn's disease [regional enteritis].
I85.00 - I85.01	Esophageal varices with or without bleeding.
Z15.09	Genetic susceptibility to other malignant neoplasm [Lynch syndrome].
Z09	Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm [reevaluation of celiac disease].

Z95.0	Presence of cardiac pacemaker.
Z96.89	Presence of other specified functional implants [electromedical devices].

OpenPayer

Capsule Endoscopy

Coverage Criteria for Capsule Endoscopy

Coding and Billing Guidance

Provider Actions, Authorization & Documentation

Definitions and Device Terms

Background, Evidence, and Outcomes

Policy Revision History